TLSI (TriSalus Life Sciences) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TLSI TriSalus Life Sciences Inc TLSI
30 GF Score
Price $4.75
GF Value $4.29
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is TriSalus Life Sciences Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

TLSI
30GF Score
TriSalus Life Sciences Inc TLSI
Total Premiums Earned is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TriSalus Life Sciences (TLSI) Overvalued in 2026?

Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued. The current stock price of $4.75 is trading 10.7% above its estimated GF Value™ of $4.29. GuruFocus considers TriSalus Life Sciences to be Modestly Overvalued.

Key valuation signals for TLSI:

  • Total Premiums Earned:
  • GF Value™: $4.29 vs. price of $4.75 (10.7% above fair value)
  • GF Score™: 30/100 with 4 warning signs

No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TriSalus Life Sciences Business Description

Address 6272 W. 91st Avenue, Westminster, CO, USA, 80031
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
30GF Score

Get the complete analysis for TLSI

Total Premiums Earned is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.75
Price
$4.29
GF Value